Orange Book product · Generic (ANDA)
POMALIDOMIDE
POMALIDOMIDE
Generic (ANDA)ANDA 209956TE ABRX TEVA PHARMS USA
At a glance
May 04, 2022
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 04, 2022
4 yr 2 mo ago
Today
Pharmaceutical detail
Active ingredient
POMALIDOMIDE
Strength
1MG
Dosage form
CAPSULE
Route
ORAL
TE code
AB
Application
ANDA 209956
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of POMALIDOMIDE
- 2013POMALYSTBrand (NDA)
NDA 204026 · BRISTOL
- 2024POMALIDOMIDEGeneric (ANDA)
ANDA 210236 · HETERO LABS LTD V
- 2024POMALIDOMIDEGeneric (ANDA)
ANDA 210164 · APOTEX
- 2022POMALIDOMIDEGeneric (ANDA)
ANDA 210275 · MYLAN
- 2020POMALIDOMIDEGeneric (ANDA)
ANDA 210111 · BRECKENRIDGE
- 2020POMALIDOMIDEGeneric (ANDA)
ANDA 210249 · EUGIA PHARMA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
